Clinical Trials Browser

Phase 1/2 × Recruiting × dupilumab × Clear all

NCT06088771 2025-05-08

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung